TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency has issued a positive opinion on the Company's Paediatric Investigation Plan for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease. An accepted PIP is a requirement for the filing for marketing authorisation of a new medicinal product with the EMA.
http://ift.tt/WwFfhx
http://ift.tt/WwFfhx
No comments:
Post a Comment